Skip to main content

Table 1 miRNAs differentially expressed between CRC and normal colorectal tissue.

From: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer

miRNA

Normala

CRCa

p-value

fold changeb

Locationc

CRC Fragile sited

hsa-miR-20a

9.2

10.3

2.0E-03

2.1

13q31.3

gain

hsa-miR-18a

7.6

8.6

2.9E-03

2.0

13q31.3

gain

hsa-miR-19a

7.7

8.7

2.3E-03

1.9

13q31.3

gain

hsa-miR-17-5p

10.5

11.4

1.5E-03

1.9

13q31.3

gain

hsa-miR-19b

11.0

11.8

3.4E-03

1.8

13q31.3

gain

hsa-miR-203

8.4

9.7

2.2E-02

2.6

14q32.33

loss

hsa-miR-21

13.0

14.5

6.0E-06

2.9

17q23.2

gain

hsa-miR-34a

9.5

10.3

1.5E-02

1.7

1p36.22

loss

hsa-miR-181b

8.5

9.2

2.2E-04

1.7

1q31.1 or 9q33.3

gain (1q)

hsa-miR-29b

9.7

10.5

4.9E-03

1.8

1q32.2 or 7q32.3

gain

hsa-miR-130b

7.1

7.8

1.2E-03

1.7

22q11.21

loss

hsa-miR-95

6.1

6.8

1.1E-02

1.6

4p16.1

loss

hsa-miR-106b

9.5

10.3

1.0E-04

1.7

7q22.1

gain

hsa-miR-93

9.9

10.5

3.4E-03

1.6

7q22.1

gain

hsa-miR-25

9.0

9.6

1.4E-02

1.6

7q22.1

gain

hsa-miR-182

7.2

8.7

2.8E-03

2.8

7q32.2

gain

hsa-miR-96

6.7

7.7

8.4E-03

2.0

7q32.2

gain

hsa-miR-183

5.9

6.8

2.3E-03

1.8

7q32.2

gain

hsa-miR-29a

12.1

12.9

3.6E-04

1.7

7q32.3

gain

hsa-miR-31

6.4

8.7

2.6E-03

5.0

9p21.3

 

hsa-miR-106a

10.7

11.7

5.1E-04

2.0

Xq26.2

 

hsa-miR-224

6.9

8.4

1.1E-03

2.8

Xq28

 

hsa-miR-30a-5p

11.6

11.0

1.6E-05

0.7

6q13

loss

hsa-miR-30a-3p

7.1

6.3

7.3E-04

0.5

6q13

loss

hsa-miR-378*

7.6

6.5

1.3E-05

0.4

5q32

loss

hsa-miR-422b

10.9

9.6

8.3E-05

0.4

5q32

loss

hsa-miR-143

14.1

12.6

1.0E-02

0.4

5q32

loss

hsa-miR-145

15.0

13.2

1.2E-03

0.3

5q32

loss

hsa-miR-10b

11.0

10.1

2.1E-02

0.5

2q31.1

 

hsa-miR-30c

10.9

10.3

4.0E-04

0.7

1p34.2 or 6q13

loss

hsa-miR-125a

11.2

10.2

6.4E-03

0.5

19q13.41

gain

hsa-miR-1

9.0

7.0

1.6E-03

0.2

18q12.3 or 20q13.33

loss (18q) or gain (20q)

hsa-miR-133a

10.0

7.6

6.5E-04

0.2

18q12.3 or 20q13.33

loss (18q) or gain (20q)

hsa-miR-497

9.3

8.1

9.8E-04

0.4

17p13.1

loss

hsa-miR-195

11.1

9.5

4.2E-05

0.3

17p13.1

loss

hsa-miR-422a

10.0

8.8

7.3E-05

0.4

15q22.31

loss

hsa-miR-139

7.6

6.2

1.1E-05

0.4

11q13.4

loss

  1. a. normalized median signal intensity (log2)
  2. b. cancer:normal
  3. c. Chromosomal location of some miRNAs equivocal since MirVana Bioarray does not discriminate between pre-miRNA precursors.
  4. d. Frequent chromosomal gains or lossesd in CRC as summarized from [31].
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us